08-03-2014, 09:11 PM
GSK posted some scary results in July, -16% revenue and flat to negative earnings, depending on which numbers you look at (income, profit, local currency vs exchange, etc). This decline was accomplished while apparently bribing doctors around the world to prescribe their products, which may have opened a whole other can of worms.
On the other hand, it does look like a tempting contrarian buy after the pullback, based on valuation and yield. They apparently have a strong pipeline aimed at 2016, which includes a diabetes drug (Tanzeum) which is my favorite pharmaceutical sector to invest in.
Thoughts?
On the other hand, it does look like a tempting contrarian buy after the pullback, based on valuation and yield. They apparently have a strong pipeline aimed at 2016, which includes a diabetes drug (Tanzeum) which is my favorite pharmaceutical sector to invest in.
Thoughts?